Brief: Oxigene gets U.S. orphan drug designation for neuroendocrine tumors drug
06/01/2016 13:01
Jan 6 (Reuters) - OXiGENE Inc OXGN.O : * Receives U.S. orphan drug designation for ca4p to treat neuroendocrine tumors * Says expect final data from this trial to be available later in 2016 * Source text for Eikon urn:newsml:reuters.com:*:nGNXMJANHa * Further company coverage OXGN.O ((Bengaluru Newsroom; +1 646 223 8780))
Recent news on Oncotelic Therapeutics
See all newsBrief: Oncotelic Therapeutics Emerging As Leader With New Independent JV Valuation
Brief: Oncotelic Therapeutics - JV Is Preparing For A Potential Initial Public Offering On The Hong Kong Stock Exchange In Late 2026
Brief: Oncotelic Therapeutics To Sell Its Necroptosis Cancer Therapy Assets To Mosaic Immunoengineering
Brief: Oncotelic Announces Initiation Of Clinical Study In Non-Small Lung Cell Cancer
Brief: Oncotelic Initiates Clinical Trials Evaluating Ot-101 Against Pediatric Gliomas